Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Lundbeck back to High Court

Posted 24 February 2021 AM

The 'Lexapro' case in which Lundbeck has been battling Sandoz and other generics makers for more than a decade, is to come before the High Court for a third time.

In the latest decision on the case, a damages award of $16 million made to Lundbeck by the Federal Court was overturned on appeal. This decision will now be subject to review by the High Court.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Approvals Action
New registrations for seizures and HIV
Eisai and ViiV add to their core franchises
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas